Author

Nitish Jangde

Georgetown UniversityORCID 0000-0002-2768-4196Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Approach:deep learning· 1 Approach:experimental assay· 1 Organism:human· 1 Organism:mouse· 1

Frequent Co-Authors

Anna M. JermakowicziD· 2 shared Jonathan ChuiD· 2 shared Luz Clarita RuiziD· 2 shared Nagi G. AyadiD· 2 shared Daniel T. WynniD· 1 shared David J. RobbinsiD· 1 shared Derek J. HansoniD· 1 shared Erik T. Goka· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 40 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersPharmacology & Toxicology

Anna M. JermakowiczORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

RAC1 Regulates Shh-Medulloblastoma Growth via GLI-Mediated Transcription

Nitish Jangde, M J Lee, Luz Clarita Ruiz, Isabelle Egan, Anna M. Jermakowicz, Rishika Chowdary, Jonathan Chu, Daniel T. Wynn, Erik T. Goka, M. E. Lippman, David J. Robbins, Nagi G. Ayad

This study identifies RAC1 as a druggable target in Shh-dependent medulloblastoma by showing its role in regulating GLI1 and GLI2 transcription and demonstrating the efficacy of the inhibitor GYS32661 in reducing tumor growth.

Neuro-Oncology · Mar 19, 2026Peer-reviewedPharmacology & Toxicology

In silico drug sensitivity predicts subgroup-specific therapeutics in medulloblastoma patients

Anna M. Jermakowicz, Luz Clarita Ruiz, Jonathan Chu, Nitish Jangde, Robert K. Suter, Nina S. Kadan‐Lottick, Derek J. Hanson, Nagi G. Ayad

This paper develops DrugSeq, a computational platform that predicts drug sensitivities in medulloblastoma subgroups, identifying subgroup-specific therapies and potential drug repositioning candidates.

Scientific Reports · Nov 27, 2025Peer-reviewedCancer Biology